Thomas P Loughran
Overview
Explore the profile of Thomas P Loughran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1003
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pal I, Illendula A, Joyner A, Manavalan J, Deddens T, Sabzevari A, et al.
bioRxiv
. 2024 Jul;
PMID: 39071370
Histone deacetylase (HDAC) inhibitors are a widely recognized and valued treatment option for patients with relapsed or refractory peripheral T cell lymphomas (PTCL). Romidepsin is a relatively selective Class I...
2.
Ung J, Tan S, Fox T, Shaw J, Taori M, Horton B, et al.
bioRxiv
. 2023 Nov;
PMID: 37961314
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy requiring urgent treatment advancements. Ceramide is a cell death-promoting signaling lipid that plays a central role in therapy-induced cell death. Acid...
3.
Loughran T, Cohn W, Bonilla G, Anderson R
Cancer Prev Res (Phila)
. 2022 Nov;
15(11):715-720.
PMID: 36317368
Prevention is a cornerstone of the guiding mission of the University of Virginia Comprehensive Cancer Center, which is "to reduce the burden of cancer for the patients of today, through...
4.
Barila G, Grassi A, Cheon H, Teramo A, Calabretto G, Chahal J, et al.
Blood
. 2022 Sep;
141(9):1036-1046.
PMID: 36096473
Tγδ large granular lymphocyte leukemia (LGLL) is a rare variant of T-cell LGLL (T-LGLL) that has been less investigated as compared with the more frequent Tαβ LGLL, particularly in terms...
5.
LeBlanc F, Hasanali Z, Stuart A, Shimko S, Sharma K, Leshchenko V, et al.
Oncotarget
. 2022 Sep;
13:986-1002.
PMID: 36093297
Classical MCL (cMCL) constitutes 6-8% of all B cell NHL. Despite recent advances, MCL is incurable except with allogeneic stem cell transplant. Blastic mantle cell lymphoma (bMCL) is a rarer...
6.
Mundy-Bosse B, Weigel C, Wu Y, Abdelbaky S, Youssef Y, Casas S, et al.
Blood Cancer Discov
. 2022 Mar;
3(2):154-169.
PMID: 35247900
Significance: Through epigenetic and transcriptomic analyses of ENKTL, a rare, aggressive malignancy, along with normal NK-cell developmental intermediates, we identified that extreme DNA hypermethylation targets genes required for NK-cell development....
7.
Cheon H, Xing J, Moosic K, Ung J, Chan V, Chung D, et al.
Blood
. 2022 Jan;
139(20):3058-3072.
PMID: 35015834
Large granular lymphocyte (LGL) leukemia comprises a group of rare lymphoproliferative disorders whose molecular landscape is incompletely defined. We leveraged paired whole-exome and transcriptome sequencing in the largest LGL leukemia...
8.
Olson T, Cheon H, Xing J, Olson K, Paila U, Hamele C, et al.
Blood
. 2021 Mar;
138(8):662-673.
PMID: 33786584
Chronic natural killer large granular lymphocyte (NK-LGL) leukemia, also referred to as chronic lymphoproliferative disorder of NK cells, is a rare disorder defined by prolonged expansion of clonal NK cells....
9.
Pearson J, Tan S, Sharma A, Annageldiyev C, Fox T, Abad J, et al.
Mol Cancer Res
. 2019 Nov;
18(3):352-363.
PMID: 31744877
Acute myeloid leukemia (AML) is a disease characterized by uncontrolled proliferation of immature myeloid cells in the blood and bone marrow. The 5-year survival rate is approximately 25%, and recent...
10.
Lamy T, Loughran T
Best Pract Res Clin Haematol
. 2019 Oct;
32(3):193-195.
PMID: 31585619
No abstract available.